TGTX Net Tangible Assets vs Current Deferred Revenue Analysis

TGTX Stock

USD 35.07 0.52 1.51%

TG Therapeutics financial indicator trend analysis is much more than just breaking down TG Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether TG Therapeutics is a good investment. Please check the relationship between TG Therapeutics Net Tangible Assets and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Net Tangible Assets vs Current Deferred Revenue

Net Tangible Assets vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of TG Therapeutics Net Tangible Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between TG Therapeutics' Net Tangible Assets and Current Deferred Revenue is -0.12. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of TG Therapeutics, assuming nothing else is changed. The correlation between historical values of TG Therapeutics' Net Tangible Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of TG Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Tangible Assets i.e., TG Therapeutics' Net Tangible Assets and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.12

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from TG Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into TG Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.At this time, TG Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 409.5 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 39.6 M in 2024.

TG Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Other Current Assets	Accounts Payable	Common Stock Total Equity	Common Stock	Other Assets	Property Plant Equipment	Short Long Term Debt Total	Short Term Investments
Total Assets		0.72	0.82	-0.03	0.8	-0.74	-0.75	0.88	0.47	0.98	0.79	0.82	0.69	0.82	1.0	-0.23	0.39	0.57	0.77	0.52	-0.11	-0.08	0.41	0.76	0.68	0.59
Other Current Liab	0.72		0.6	-0.44	0.66	-0.58	-0.62	0.7	0.79	0.73	0.61	0.66	0.5	0.65	0.69	-0.15	0.13	0.49	0.86	0.02	0.01	0.02	0.13	0.78	0.56	0.19
Total Current Liabilities	0.82	0.6		-0.32	0.96	-0.56	-0.8	0.71	0.47	0.8	0.84	0.68	0.73	0.96	0.82	-0.28	0.28	0.61	0.64	0.7	-0.13	-0.11	0.3	0.8	0.68	0.53
Total Stockholder Equity	-0.03	-0.44	-0.32		-0.48	-0.07	0.44	-0.06	-0.69	-0.06	-0.34	-0.26	-0.29	-0.44	0.02	0.08	0.22	-0.37	-0.41	-0.02	-0.06	-0.05	0.23	-0.34	-0.36	0.09
Property Plant And Equipment Net	0.8	0.66	0.96	-0.48		-0.48	-0.87	0.67	0.56	0.78	0.87	0.75	0.74	1.0	0.79	-0.25	0.3	0.71	0.74	0.64	-0.05	-0.03	0.32	0.82	0.78	0.55
Net Debt	-0.74	-0.58	-0.56	-0.07	-0.48		0.21	-0.96	-0.35	-0.85	-0.27	-0.33	-0.16	-0.44	-0.75	0.13	0.27	0.09	-0.31	-0.13	0.03	0.05	0.25	-0.5	-0.06	0.05
Retained Earnings	-0.75	-0.62	-0.8	0.44	-0.87	0.21		-0.46	-0.54	-0.66	-0.98	-0.94	-0.85	-0.9	-0.74	0.26	-0.6	-0.92	-0.88	-0.7	0.09	0.05	-0.6	-0.77	-0.95	-0.79
Cash	0.88	0.7	0.71	-0.06	0.67	-0.96	-0.46		0.47	0.96	0.49	0.55	0.37	0.64	0.88	-0.17	-0.07	0.18	0.53	0.27	-0.03	-0.04	-0.05	0.65	0.32	0.16
Non Current Assets Total	0.47	0.79	0.47	-0.69	0.56	-0.35	-0.54	0.47		0.5	0.52	0.51	0.53	0.53	0.42	-0.12	-0.06	0.41	0.68	-0.01	-0.08	-0.09	-0.07	0.52	0.46	0.06
Cash And Short Term Investments	0.98	0.73	0.8	-0.06	0.78	-0.85	-0.66	0.96	0.5		0.7	0.74	0.59	0.77	0.98	-0.22	0.2	0.43	0.69	0.44	-0.09	-0.07	0.22	0.73	0.55	0.44
Common Stock Shares Outstanding	0.79	0.61	0.84	-0.34	0.87	-0.27	-0.98	0.49	0.52	0.7		0.92	0.91	0.9	0.78	-0.35	0.6	0.89	0.84	0.75	-0.24	-0.2	0.61	0.78	0.9	0.82
Other Stockholder Equity	0.82	0.66	0.68	-0.26	0.75	-0.33	-0.94	0.55	0.51	0.74	0.92		0.78	0.79	0.81	-0.24	0.6	0.85	0.91	0.62	-0.09	-0.05	0.61	0.76	0.88	0.78
Total Liab	0.69	0.5	0.73	-0.29	0.74	-0.16	-0.85	0.37	0.53	0.59	0.91	0.78		0.78	0.67	-0.38	0.6	0.8	0.73	0.64	-0.36	-0.32	0.61	0.61	0.81	0.79
Property Plant And Equipment Gross	0.82	0.65	0.96	-0.44	1.0	-0.44	-0.9	0.64	0.53	0.77	0.9	0.79	0.78		0.8	-0.25	0.39	0.76	0.77	0.67	-0.06	-0.03	0.4	0.82	0.83	0.62
Total Current Assets	1.0	0.69	0.82	0.02	0.79	-0.75	-0.74	0.88	0.42	0.98	0.78	0.81	0.67	0.8		-0.23	0.4	0.56	0.74	0.54	-0.1	-0.07	0.42	0.74	0.67	0.61
Non Currrent Assets Other	-0.23	-0.15	-0.28	0.08	-0.25	0.13	0.26	-0.17	-0.12	-0.22	-0.35	-0.24	-0.38	-0.25	-0.23		-0.1	-0.17	-0.18	-0.29	0.36	0.36	-0.11	-0.34	-0.16	-0.23
Net Receivables	0.39	0.13	0.28	0.22	0.3	0.27	-0.6	-0.07	-0.06	0.2	0.6	0.6	0.6	0.39	0.4	-0.1		0.8	0.55	0.48	-0.08	0.0	1.0	0.29	0.76	0.91
Non Current Liabilities Total	0.57	0.49	0.61	-0.37	0.71	0.09	-0.92	0.18	0.41	0.43	0.89	0.85	0.8	0.76	0.56	-0.17	0.8		0.84	0.59	-0.06	-0.01	0.8	0.6	0.98	0.85
Other Current Assets	0.77	0.86	0.64	-0.41	0.74	-0.31	-0.88	0.53	0.68	0.69	0.84	0.91	0.73	0.77	0.74	-0.18	0.55	0.84		0.33	-0.01	0.03	0.55	0.78	0.88	0.62
Accounts Payable	0.52	0.02	0.7	-0.02	0.64	-0.13	-0.7	0.27	-0.01	0.44	0.75	0.62	0.64	0.67	0.54	-0.29	0.48	0.59	0.33		-0.22	-0.19	0.5	0.49	0.58	0.76
Common Stock Total Equity	-0.11	0.01	-0.13	-0.06	-0.05	0.03	0.09	-0.03	-0.08	-0.09	-0.24	-0.09	-0.36	-0.06	-0.1	0.36	-0.08	-0.06	-0.01	-0.22		1.0	-0.08	0.1	-0.03	-0.18
Common Stock	-0.08	0.02	-0.11	-0.05	-0.03	0.05	0.05	-0.04	-0.09	-0.07	-0.2	-0.05	-0.32	-0.03	-0.07	0.36	0.0	-0.01	0.03	-0.19	1.0		-0.01	0.12	0.03	-0.11
Other Assets	0.41	0.13	0.3	0.23	0.32	0.25	-0.6	-0.05	-0.07	0.22	0.61	0.61	0.61	0.4	0.42	-0.11	1.0	0.8	0.55	0.5	-0.08	-0.01		0.29	0.76	0.92
Property Plant Equipment	0.76	0.78	0.8	-0.34	0.82	-0.5	-0.77	0.65	0.52	0.73	0.78	0.76	0.61	0.82	0.74	-0.34	0.29	0.6	0.78	0.49	0.1	0.12	0.29		0.65	0.46
Short Long Term Debt Total	0.68	0.56	0.68	-0.36	0.78	-0.06	-0.95	0.32	0.46	0.55	0.9	0.88	0.81	0.83	0.67	-0.16	0.76	0.98	0.88	0.58	-0.03	0.03	0.76	0.65		0.84
Short Term Investments	0.59	0.19	0.53	0.09	0.55	0.05	-0.79	0.16	0.06	0.44	0.82	0.78	0.79	0.62	0.61	-0.23	0.91	0.85	0.62	0.76	-0.18	-0.11	0.92	0.46	0.84

Click cells to compare fundamentals

TG Therapeutics Account Relationship Matchups

TG Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	163.0M	625.6M	379.6M	193.6M	329.6M	346.1M
Other Current Liab	5.4M	26.7M	61.5M	8.0M	13.5M	14.2M
Total Current Liabilities	84.4M	87.6M	65.4M	53.2M	53.7M	56.4M
Total Stockholder Equity	(701.2M)	519.4M	(1.3B)	(1.5B)	160.5M	168.5M
Property Plant And Equipment Net	11.8M	11.8M	11.1M	10.8M	8.1M	8.6M
Net Debt	(71.8M)	(511.5M)	(219.8M)	(19.2M)	17.9M	18.8M
Retained Earnings	(701.2M)	(980.6M)	(1.3B)	(1.5B)	(1.5B)	(1.4B)
Cash	112.6M	553.4M	298.9M	102.3M	92.9M	59.3M
Non Current Assets Total	13.9M	13.9M	48.7M	25.3M	11.6M	7.5M
Cash And Short Term Investments	140.4M	605.4M	350.3M	174.1M	217.5M	228.4M
Common Stock Shares Outstanding	88.4M	115.3M	132.2M	135.4M	148.5M	155.9M
Liabilities And Stockholders Equity	(576.8M)	625.6M	(1.2B)	(1.4B)	329.6M	346.1M
Other Stockholder Equity	(109K)	1.5B	1.6B	1.6B	1.7B	1.8B
Total Liab	124.4M	106.3M	142.5M	135.0M	169.1M	177.5M
Property Plant And Equipment Gross	11.8M	11.8M	11.1M	10.8M	9.6M	10.0M
Total Current Assets	149.2M	611.7M	331.0M	168.3M	317.9M	333.8M
Non Currrent Assets Other	1.3M	1.3M	1.3M	1.3M	1.4M	1.3M
Net Receivables	108.5K	95K	0.0	1.4M	51.1M	53.6M
Non Current Liabilities Total	40.0M	18.7M	77.1M	81.8M	115.4M	121.1M
Other Current Assets	611K	6.3M	14.8M	6.6M	9.5M	10.0M
Accounts Payable	30.0M	37.0M	(457K)	42.0M	38.5M	40.4M
Common Stock Total Equity	109K	141K	143K	146K	131.4K	74.7K
Common Stock	109K	141K	143K	146K	151K	105.2K
Other Assets	3.4M	13.1M	3.1M	2.9M	329.6M	346.1M
Property Plant Equipment	282K	481K	600K	307K	353.1K	370.7K
Short Long Term Debt Total	40.8M	42.0M	79.0M	83.1M	110.8M	116.3M
Short Term Investments	27.8M	52.0M	15.9M	59.4M	124.6M	130.8M
Other Liab	762K	610K	457K	305K	274.5K	260.8K
Short Term Debt	1.6M	23.8M	3.8M	3.2M	1.4M	2.8M
Net Tangible Assets	37.8M	518.6M	310.7M	57.8M	66.5M	118.5M
Retained Earnings Total Equity	(701.2M)	(980.6M)	(1.3B)	(1.5B)	(1.4B)	(1.3B)
Capital Surpluse	740.0M	1.5B	1.6B	1.6B	1.8B	1.9B
Deferred Long Term Liab	762K	610K	457K	305K	274.5K	260.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

TGTX Net Tangible Assets vs Current Deferred Revenue Analysis

Net Tangible Assets vs Current Deferred Revenue

Net Tangible Assets vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Current Deferred Revenue

TG Therapeutics fundamental ratios Correlations

TG Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

TG Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for TGTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Other Assets	+ 1.0	Net Receivables
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Cash And Short Term Investments

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Cash	- 0.96	Net Debt
Short Long Term Debt Total	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Non Current Liabilities Total	- 0.92	Retained Earnings
Property Plant And Equipment Gross	- 0.9	Retained Earnings